These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 4943087)

  • 1. Reduction of catechol-O-methyl-transferases activity by chronic L-dopa therapy.
    Weiss JL; Cohn CK; Chase TN
    Nature; 1971 Nov; 234(5326):218-9. PubMed ID: 4943087
    [No Abstract]   [Full Text] [Related]  

  • 2. Blood catechol-O-methyltransferase activity in Parkinson's disease.
    Frère JM; Barbeau A
    Lancet; 1971 Jul; 2(7718):269-70. PubMed ID: 4104811
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of chronic administration of L-dopa on catechol-O-methyltransferase in rat tissues.
    Sharpless NS; Tyce GM; Owen CA
    Life Sci I; 1973 Feb; 12(3):97-106. PubMed ID: 4696602
    [No Abstract]   [Full Text] [Related]  

  • 4. Emotional functions in short-term vs. long-term L-Dopa therapy in Parkinsonism.
    Maskin MB; Riklan M; Chabot D
    J Clin Psychol; 1973 Oct; 29(4):493-5. PubMed ID: 4148857
    [No Abstract]   [Full Text] [Related]  

  • 5. Decrease of the 3,4-dihydroxyphenylalanine (DOPA) decarboxylase activities in human erythrocytes and mouse tissues after administration of DOPA.
    Tate SS; Sweet R; McDowell FH; Meister A
    Proc Natl Acad Sci U S A; 1971 Sep; 68(9):2121-3. PubMed ID: 5289372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the mode of action of L-dopa in Parkinson's disease.
    Sourkes TL
    Biochem Med; 1970 Feb; 3(4):321-5. PubMed ID: 4943208
    [No Abstract]   [Full Text] [Related]  

  • 7. Potentiation of the L-Dopa effect in man by the use of catechol-O-methyltransferase inhibitors.
    Ericsson AD
    J Neurol Sci; 1971 Oct; 14(2):193-7. PubMed ID: 5112212
    [No Abstract]   [Full Text] [Related]  

  • 8. Some quantitative behavioral changes in L-dopa therapy.
    Meier MJ; Baker AB; Martin WE
    Geriatrics; 1972 Jun; 27(6):89-97. PubMed ID: 5032486
    [No Abstract]   [Full Text] [Related]  

  • 9. [Theray of Parkinson-syndrome with Helfo-Dopa].
    Roeder F
    Med Klin; 1970 Nov; 65(45):1983-7. PubMed ID: 5520307
    [No Abstract]   [Full Text] [Related]  

  • 10. Intellectual and memory function in parkinsonian and non-parkinsonian patients treated with L-dopa.
    Donnelly EF; Chase TN
    Dis Nerv Syst; 1973 Feb; 34(2):119-23. PubMed ID: 4706860
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of catechol-O-methyl transferase by L-dopa and decarboxylase inhibitors.
    Baldessarini RJ
    J Pharm Pharmacol; 1972 Jan; 24(1):78-80. PubMed ID: 4401326
    [No Abstract]   [Full Text] [Related]  

  • 12. Erythrocytes catechol-o-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients.
    Maltête D; Cottard AM; Mihout B; Costentin J
    Clin Neuropharmacol; 2011; 34(1):21-3. PubMed ID: 21164341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of L-dopa on plasma free fatty acids and plasma glucose.
    Rivera-Calimlim L; Bianchine JR
    Metabolism; 1972 Jul; 21(7):611-7. PubMed ID: 5040916
    [No Abstract]   [Full Text] [Related]  

  • 14. Stimulation of human-growth-hormone secretion by L-dopa.
    Boyd AE; Lebovitz HE; Pfeiffer JB
    N Engl J Med; 1970 Dec; 283(26):1425-9. PubMed ID: 5481776
    [No Abstract]   [Full Text] [Related]  

  • 15. L-dopa in the treatment of post-surgical Parkinson patients.
    Wycis HT; Cunningham W; Kellett G; Spiegel EA
    J Neurosurg; 1970 Mar; 32(3):281-5. PubMed ID: 5416910
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical pharmacology as an approach to the study of biochemical sleep mechanisms: the action of L-dopa.
    Bergonzi P; Chiurulla C; Cianchetti C; Tempesta E
    Confin Neurol; 1974; 36(1):5-22. PubMed ID: 4363375
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of L-dopa therapy on urinary p-tyramine excretion and EEG changes in Parkinson's disease.
    Boulton AA; Marjerrison GL
    Nature; 1972 Mar; 236(5341):76-8. PubMed ID: 4553458
    [No Abstract]   [Full Text] [Related]  

  • 18. [Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].
    Gauthier G; de Ajuriaguerra J; Geissbuhler F; Simona B; Constantinidis J; Yanniotis G; Krassoievitch M; Eisenring JJ; Tissot R
    Presse Med (1893); 1971 Jan; 79(3):91-2. PubMed ID: 5539694
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term treatment of Parkinsonism with L-dopa.
    Presthus J; Holmsen R
    Acta Neurol Scand Suppl; 1972; 51():131-2. PubMed ID: 4514340
    [No Abstract]   [Full Text] [Related]  

  • 20. L-glutamic acid decarboxylase in Parkinson's disease: effect of L-dopa therapy.
    Lloyd KG; Hornykiewicz O
    Nature; 1973 Jun; 243(5409):521-3. PubMed ID: 4743649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.